RECRUITINGOBSERVATIONAL

Quantitative-imaging in Cardiac Transthyretin Amyloidosis

About This Trial

Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis. Several novel expensive treatments have become available, although we do not understand exactly how they work and why some patients respond, and others do not. The challenge is to develop better methods for monitoring the effects of these treatments, maximizing their benefits and cost-effectiveness. In I-CARE we aim to bring a new imaging technique, named 18F-fluoride PET, to the clinic and thereby improve the care of patients with ATTR-CM. Hypotheses: 1. A delayed imaging protocol and state-of-the-art PET motion correction will optimise 18F-fluoride imaging in ATTR-CM and provide a clear threshold in myocardial TBR values for the diagnosis of ATTR-CM. 2. Optimised 18F-fluoride PET will provide a quantitative marker of the ATTR-CM burden that will allow disease progression and treatment response to be tracked. 3. Myocardial 18F-fluoride TBR values will reduce in patients responding to tafamidis treatment and increase in non-responders and patients not receiving therapy

Who May Be Eligible (Plain English)

Who May Qualify: - Completion of willing to sign a consent form - Age \> 40 years for patients with ATTR or AL cardiac amyloidosis and age \>30 years for patients with HCM - ATTR cardiac amyloid according to Expert Consensus Recommendations - AL amyloidosis according to Expert Consensus Recommendations - Hypertrophic cardiomyopathy according to European Society of Cardiology guidelines Who Should NOT Join This Trial: - Inability or unwilling to give willing to sign a consent form - Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial. - Renal dysfunction (eGFR ≤30 mL/min/1.73m2) - NYHA Class IV heart failure - Patients with atrial fibrillation and poor rate control. - Contraindications to MR - Previous history of contrast allergy of adverse reactions (gadolinium) - Contraindications to tafamidis therapy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Completion of informed consent * Age \> 40 years for patients with ATTR or AL cardiac amyloidosis and age \>30 years for patients with HCM * ATTR cardiac amyloid according to Expert Consensus Recommendations * AL amyloidosis according to Expert Consensus Recommendations * Hypertrophic cardiomyopathy according to European Society of Cardiology guidelines Exclusion Criteria: * Inability or unwilling to give informed consent * Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial. * Renal dysfunction (eGFR ≤30 mL/min/1.73m2) * NYHA Class IV heart failure * Patients with atrial fibrillation and poor rate control. * Contraindications to MR * Previous history of contrast allergy of adverse reactions (gadolinium) * Contraindications to tafamidis therapy

Treatments Being Tested

RADIATION

18F-fluoride PET

Positron emission tomography using 18F-fluoride as a tracer

Locations (1)

University Medical Centre Groningen

Groningen, Netherlands